C5 and familial isolated congenital asplenia: Under this regulation, the bivalent meningococcal polysaccharide vaccine (MenAC) was indicated, based on clinical criteria, for patients aged ≥2 years with anatomical or functional asplenia, for those with complement (C5–C9) deficiencies, as well as for international travelers [11].